Please ensure Javascript is enabled for purposes of website accessibility

Here's Why BioNTech Jumped Today

By Maxx Chatsko – Jun 29, 2020 at 1:06PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The German biopharma announced a $250 million private investment.

What happened

Shares of BioNTech (BNTX 2.08%) rose as much as 14.9% today after the company announced a private placement of approximately $250 million. Temasek, Singapore's state investor, agreed to purchase $139 million in common stock and $112 million in convertible debt. 

BioNTech is working on a coronavirus vaccine based on its mRNA technology platform. Pfizer (PFE 0.59%) has thrown its capital, reputation, and institutional knowledge behind the effort and the development-stage biopharma, which has catapulted the German company into the global spotlight. 

As of 12:37 p.m. EDT, the pharma stock had settled to a 8.3% gain.

An arrow bouncing up shelves on a wall.

Image source: Getty Images.

So what

BioNTech has leveraged its visibility as one of the most closely watched coronavirus vaccine developers to greatly expand its financial flexibility. The German biopharma ended March with $495 million in cash and expecting another $236 million in equity investments and nondilutive upfront payments due from partners Pfizer and Fosun Pharma in the second quarter of 2020, and it had over $100 million in debt financing extended by the European Investment Bank in June.

The business will surely need hundreds of millions of dollars to expedite clinical trials for its coronavirus vaccine candidates, scale manufacturing, and plan large-scale distribution of its vaccine product -- assuming that product proves to be safe and effective, of course.

It's not too surprising Temasek came knocking. The group has steadily increased investments in living technologies in the last decade, including companies in biopharma, industrial biotech, and agricultural biotech.

Now what

BioNTech is well funded and has a solid development strategy in place to test multiple vaccine candidates. The world will need multiple successful coronavirus vaccines to beat the pandemic, so investors shouldn't be too concerned about the company being the first to report successful results. What matters most is delivering a safe and effective vaccine. 

Maxx Chatsko has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

BioNTech SE Stock Quote
BioNTech SE
$130.30 (2.08%) $2.65
Pfizer Inc. Stock Quote
Pfizer Inc.
$44.09 (0.59%) $0.26

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.